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ALLERGIC CONJUNCTIVITIS IN OXFORDSHIRE,
ENGLAND
Smith AF
Alcon Laboratories Ltd and Nufﬁeld Laboratory of
Ophthalmology, University of Oxford, Hemel Hempstead,
Hertfordshire, United Kingdom
OBJECTIVES: The purpose of this study was to examine
the economic and quality of life (QoL) impact of seasonal
allergic conjunctivitis (SAC) in Oxfordshire, England.
METHODS: The inclusion criteria for cases were that
participants: 1) experienced itchy, bloodshot and water-
ing eyes at some time between February and August every
year since 1999, and 2) considered it likely that this was
in response to seasonal allergens. Controls were drawn
from the same sources and were age and sex-matched 
to cases. Participants completed the EQ-5D Health 
Questionnaire, the Rhinoconjunctivitis Quality of Life
Questionnaire, the National Eye Institute (US) Visual
Functioning Questionnaire 25, and a specially developed
Health Economic and Demographic Questionnaire.
RESULTS: Most participants in both groups were female
(67.5% in SAC and 70% in control group, P = 0.565).
Weekly earnings were lower in the SAC group (P <
0.001), as the SAC group also worked fewer hours per
week (P < 0.001). Participants with SAC also experienced
a greater degree of pain and discomfort as measured by
the EQ-5D (P = 0.018) and a lower perception of their
health status using the EQ-VAS (P = 0.039). Statistically
signiﬁcant differences between both groups were detected
in all domains of the VFQ-25, except general and colour
vision, although differences were thought to be clinically
signiﬁcant only for the ocular pain domain. The RQLQ
scores were also all found to differ signiﬁcantly between
groups (P < 0.001). The total of both the public health
care and private out-of-pockets costs of SAC in our study
population ranged on average between £64.61 for a pen-
sioner to £142.29 for a person with SAC in paid employ-
ment. CONCLUSIONS: SAC is a costly, highly prevalent,
chronic condition associated with signiﬁcant reductions
in both ocular and general quality of life, as well as
ongoing out-of-pocket expenses and health care costs.
ALLERGY—Quality of Life Studies
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THE EYE ALLERGY PATIENT IMPACT
QUESTIONNAIRE (EAPIQ)
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OBJECTIVES: The EAPIQ was developed based on a
pilot study conducted in the US and focus groups with
eye allergy sufferers in Europe. The purpose of this study
is to present the results of the EAPIQ’s construct valid-
ity and reliability testing. METHODS: A total of 146
patients from 2 allergy clinics completed the EAPIQ twice
over a two-week period during the fall and winter allergy
seasons, along with concurrent measures of health status,
work productivity, and utility. Construct validity, 
reliability and known groups validity were assessed.
RESULTS: Results from the validation study suggested
the deletion of 14 items that required patients to com-
plete the percentage of time they were troubled by some-
thing (daily activity limitations/emotional troubles).
These questions yielded a signiﬁcant amount of missing
or inconsistent data (50%). The resulting factor analysis
suggested four domains: symptoms, daily activity limita-
tions, emotional well-being, and treatment satisfaction.
The relative merits of assessing symptom-bother sepa-
rately from symptom-frequency were also assessed.
Results indicated that the two scales were highly corre-
lated (>0.9) and known groups validity testing suggested
the superior discriminative ability of the symptom fre-
quency measure (F = 44.63 vs 39.63). However, when
symptom bother and frequency items were summated dis-
criminative validity was superior (F = 45.29). As a result,
it was decided to sum the symptom bother and frequency
items. All items met the tests for item convergent validity
(item-scale correlation >=0.4). The success rate for item
discriminant validity testing was 97% (item-scale corre-
lation greater with own scale than with any other). Inter-
nal consistency reliability criterion (>=0.7) were met for
all scales (range 0.89–0.93). Ongoing work will assess the
test-retest reliability and known groups’ validity of the
EAPIQ. CONCLUSIONS: Asking patients to write in
responses can lead to inconsistent responses or missing
data. With the deletion of those items, the EAPIQ 
was found to have satisfactory construct validity and 
reliability.
EYE DISEASES OR DISORDERS
EYE DISEASES OR DISORDERS—Clinical
Outcomes Studies
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OBJECTIVES: To estimate the prevalence of low vision
(LV) and blindness in France. METHODS: Two national
surveys were pooled together: 1) 2075 institutions (for
children or adults with handicaps, the aged, and psychi-
atric centers) were selected at random from the French
Health Ministry ﬁles in 18 predeﬁned strata. Of the
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15,403 subjects taken at random, 14,603 interviews
(94.9%) were completed. 2) A random, stratiﬁed sample
of 356,208 citizens living in the community was selected.
From this sample, 21,760 subjects were further selected
at random and 16,945 persons were interviewed. Three
groups were deﬁned, based upon subject interviews:
blind, low vision (LV), and a control group (CG). Blind-
ness and LV prevalence rates by age and gender were esti-
mated. Extrapolation weights for France came from 
the 1999 national census survey. Geographical inequities
were estimated with a logistic regression adjusted by age
and occupational category. RESULTS: The prevalence
rates of blindness and LV were 0.12% and 2.08%, respec-
tively. They increased exponentially with age. No major
difference was found by gender. 51.4% of blind subjects
and 22.8% of the LV subjects declared they are included
in a long-term disease registry. Aging was the most often
declared (34.1%) reason for LV; post-natal diseases were
most often cited (50.3%) for blindness. Injuries repre-
sented about 12% of the reasons for both blindness and
LV. Large region differences in LV prevalence persisted
after adjustment (OR: 0.35 to 2.10). This was not the case
for blindness prevalence. Regions whose rates of oph-
thalmologists per capita were lower than the national
average more often had statistically signiﬁcant higher LV
prevalence (43.8% versus 6.3%). CONCLUSION: LV is
much more frequent than blindness. Aging was the most
cited reason for LV. The inverse correlation between the
number of ophthalmologists and the prevalence of LV
suggests that further public health investments might help
control the effect of aging on vision.
PAE6
PREVALENCE AND BURDEN OF BLINDNESS
AND LOW VISION IN SUBJECTS LIVING IN
INSTITUTIONS: A NATION-WIDE SURVEY
Brézin A1, Lafuma A2, Fagnani F3, Mesbah M4, Berdeaux G5
1Hopital COCHIN, Paris, France; 2Cemka, Bourg-La-Reine,
France; 3CEMKA, Bourg la Reine, France; 4Université de
Bretagne-Sud,Vannes, France; 5Alcon, Rueil-Malmaison, France
OBJECTIVES: To estimate the prevalence of low vision
(LV) and blindness, and their associated disabilities,
handicaps and socio-economic consequences in subjects
living in institutions. METHODS: Two thousand seventy-
ﬁve institutions (children or adults with handicaps, old
people and psychiatric centers) were selected at random
from the French Health Ministry ﬁles in 18 predeﬁned
strata. Day care centers were excluded. In each selected
institution, eight subjects were picked at random by 
the interviewers from the resident list. Face-to-face inter-
views collected social and demographic data, institu-
tion description, income, handicaps, disabilities, social
allowances and activities of daily living. Three groups
were deﬁned based upon subject interviews: blind, low
vision (LV), and a control group (CG). These were com-
pared after adjustment for age and co-morbidities. Of the
15,403 subjects selected at random, 14,603 interviews
(94.9%) were completed. RESULTS: The prevalence of
blindness was 1.6% and the low vision ﬁgure was 13.4%.
The CG was younger than blind and LV subjects (67.3,
71.4 and 80). Entry to institutions was related to health
in more than 75% of the cases. Blind subjects needed
assistance with daily activities more often (RR: 1.31 to
3.33) than CG members while LV subjects’ assistance was
similar to that of the CG. Blind subjects often required
more institution adaptation than the CG (RR: 1.13 to
2.83). Blind (57.9%) and LV subjects (35.4%) were more
often registered for social allowances. Monthly social
allowances were €86 higher for blind than LV individu-
als. Monthly family incomes were found similar between
the 3 groups (from €782 to 797). CONCLUSION: The
results demonstrate the impact of blindness and LV on
daily living in patients living in institutions.
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OBJECTIVES: The targets of this study was to estimate
the prevalence of low vision and blindness, their associ-
ated disabilities, handicaps and socio-economic conse-
quences. METHODS: A national survey was conducted
on a random, stratiﬁed sample of 356,208 French citizens
living in the community. From this sample, 21,760 sub-
jects were further selected at random and 16,945 persons
were interviewed. Also, 4,091 randomly selected domes-
tic carers were interviewed. Handicap data were gathered
by means of an 18-item questionnaire. Collected data
included social demography, home description, house-
hold income, handicaps, disabilities, social allowances
and activities of daily living. Four groups were created,
based upon subject interviews (blind, low vision (LV),
other visual defects (OVD) and no visual problems
(NVP)). These were compared after adjustment on age,
co-morbidity and household size. RESULTS: The preva-
lence of blindness was 0.10% and of low vision 1.94%.
Persons with no visual problems had less co-morbidity
(0.81) than those with LV (1.39), or blindness (1.33).
Blind subjects needed assistance with daily activities more
often (Odds-Ratio: 2.6 to 56.6) than NVP subjects and
needed house modiﬁcations. Many blind (46.8%) and LV
subjects (29.0%) were registered for social allowances.
Blind subjects had fewer paid activities (4.5%) than 
subjects did with no visual problems (20.7%). Social
allowances increased considerably, by €277, between LV
and blind persons. Monthly household incomes were
lower for LV (€1255) and blind subjects (€1587) than 
for NVP subjects (€1851). CONCLUSION: The results
demonstrate the impact of blindness and low vision on
daily living.
